Figure 2 | Scientific Reports

Figure 2

From: Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection

Figure 2

Vorinostat dosing resulted in induction of HDACi-responsive host genes in PBMCs. PBMCs were collected immediately prior to the 1st VOR dose, after the 5th and 10th q72h dose, and 7–10 days after the 10th dose during cycle I and II. Expression of HDACi-responsive host genes was assessed relative to the pre-dose time point for each cycle. Error bars represent standard deviation of the mean of triplicate cDNA preparations, each conducted in duplicate qPCR reactions.

Back to article page